Cardinal Health, Inc. (CAH) Stock: Price, Forecast & Analyst Target
Cardinal Health, Inc. (CAH) — MoonshotScore 88/100 (Exceptional band), calculated Oct 4, 2026. Price $228.30 (-0.78%), as of the Oct 2, 2026 trading session; market cap $53.5B. Expected results Oct 29, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 11.02× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 29, 2026
Cardinal Health, Inc. · CAH · NYSE · Healthcare · Medical - Distribution
Research dated 2026-09-12: Cardinal Health moves pharmaceuticals and healthcare supplies through hospitals, pharmacies, clinical facilities, physician practices, and home-care channels, while also manufacturing selected medical products and operating specialized pharmaceutical services. The case depends on whether richer gross profit and dependable cash conversion can outweigh distribution-thin margins, pharmaceutical concentration, and debt that exceeds cash.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Cardinal Health (CAH)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet and elite growth, at a dirt-cheap price, though quality is only decent; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $63.86B (Q4 FY2026, quarter ended Jun 2026)
- EPS beat 8 of 8
- expected results Oct 29, 2026
Helping: balance-sheet strength, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional |
The score was 88 in the stored Oct 3, 2026 snapshot and remains 88 in the current publication computed Oct 4, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $228.30 | |
| Change on the day | -0.78% | |
| 52-week range | $151.87 – $258.30 | |
| Market capitalisation | $53.5B | |
| Price / earnings (trailing) | 31.40 | |
| Shares traded on the day | 1.82M | |
| Beta (volatility vs the S&P 500) | 0.52 | |
| Dividends per share (last 12 months) | $2.05 | |
| Dividend yield (last 12 months) | 0.90% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect Pharma segment revenue to show 3% to 5% growth in the coming year.
Aaron Alt · Statement from
First, from a baseline perspective, for ease of comparability between fiscal '26 and our guidance for future years, we will be excluding the $0.31 of onetime positive EPS impact from the IEEPA tariff refund recognition in our just past Q4.
Aaron Alt · Statement from
Chronological order, not a duration scale. Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Cardinal Health (CAH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the CAH film — every key number, told as a short cinematic story
~2 min · open the film
What is Cardinal Health (CAH), and what does it report?
Short answer · as of
Most revenue comes from distributing branded, generic, specialty, and consumer health products rather than inventing new medicines.
Research dated 2026-09-12.
Most revenue comes from distributing branded, generic, specialty, and consumer health products rather than inventing new medicines. Cardinal Health also runs nuclear pharmacies, produces radiopharmaceuticals, repackages drugs, manages hospital pharmacies, and provides services for manufacturers, providers, and payers.
The Medical operation manufactures, sources, and distributes Cardinal Health-branded and national-brand supplies, devices, procedure kits, and laboratory products. Reported sales therefore include enormous volumes of pharmaceutical and medical product value passing through the network; the segment mix and narrow gross margin show why revenue is vast while the retained profit on each sales dollar is small.
What do the latest results show for Cardinal Health (CAH)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $63.86B.
Research dated 2026-09-12.
The latest annual period delivered higher revenue and net income than the preceding annual period. In the latest quarter, revenue, gross profit, and operating profit advanced from the prior period, while net income edged lower; reported earnings have repeatedly exceeded estimates even though revenue has fallen short of consensus in the latest releases.
Management expects Pharmaceutical revenue to keep growing and points to expanding management-service platforms and distribution wins that began ramping recently. It is excluding a tariff-refund benefit from the comparison baseline because that benefit was nonrecurring, making underlying profit progression the more informative test.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $63.86B Jun 30, 2026
- Latest quarter · SG&A
- $1.63B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $729.00M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $63.86B | Not available | $1.63B | $729.00M |
| Mar 31, 2026 | $60.94B | Not available | $1.54B | $509.00M |
| Dec 31, 2025 | $65.44B | Not available | $1.50B | $707.00M |
| Sep 30, 2025 | $64.01B | Not available | $1.46B | $668.00M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $63.67B Aug 11, 2026
- Latest report · revenue estimate
- $65.15B Aug 11, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 11, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 11, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 11, 2026 | $63.67B | $65.15B | $2.9100 | $2.4200 |
| Apr 30, 2026 | $60.94B | $62.10B | $3.1700 | $2.7900 |
| Feb 5, 2026 | $65.63B | $65.08B | $2.6300 | $2.3400 |
| Oct 30, 2025 | $64.01B | $59.24B | $2.5500 | $2.1800 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $63.86B | $394M | $1.69 (diluted) |
| Q3 FY2026 | $60.94B | $399M | $1.69 (diluted) |
| Q2 FY2026 | $65.44B | $471M | $1.97 (diluted) |
| Q1 FY2026 | $64.01B | $450M | $1.88 (diluted) |
What are the financial strengths and risks for Cardinal Health (CAH)?
Short answer
Cash and short-term investments were $4.86B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $1.69B for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has recovered sharply from earlier outflows and stayed positive through the recent run, with capital spending consuming only part of that inflow. Cash and short-term investments have also risen, but debt remains materially greater than cash, while short-term liquidity ratios sit below parity.
Cardinal Health earns a very narrow gross and operating margin on a pharmaceutical-heavy revenue base. A modest deterioration in the spread between product cost and selling price could therefore have an outsized effect on operating profit, even without a major change in sales volume; the favorable distress and accounting-quality screens do not remove that operating sensitivity.
Data-derived red flags
- Negative return on equity (-55.7%) — the business is not currently generating profit on shareholder capital.
- Rich valuation — a P/E of 31.40 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $1.69B Jun 30, 2026
- Previous quarter · operating cash flow
- $1.82B Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $1.69B | −$264.00M |
| Mar 31, 2026 | $1.82B | −$146.00M |
| Dec 31, 2025 | $686.00M | −$131.00M |
| Sep 30, 2025 | $973.00M | −$108.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Cardinal Health (CAH)?
Short answer · as of
The next earnings report is expected on Oct 29, 2026.
Research dated 2026-09-12.
At the scheduled earnings release, compare Pharmaceutical revenue direction with management's growth expectation and look for evidence that the expanding management-service platforms and recently ramped distribution wins are contributing to gross profit, not merely sales. Recent earnings beats alongside revenue misses make gross-profit and operating-profit progression more revealing than the top line alone.
Cash conversion deserves the same attention: sustained operating inflow after capital spending would reinforce the recent recovery, while renewed working-capital outflows would weaken it. Longer-range estimates assume continued expansion in revenue and earnings, so any break in that pattern would change the expectations surrounding the business.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We expect Pharma segment revenue to show 3% to 5% growth in the coming year.
Aaron Alt ·
First, from a baseline perspective, for ease of comparability between fiscal '26 and our guidance for future years, we will be excluding the $0.31 of onetime positive EPS impact from the IEEPA tariff refund recognition in our just past Q4.
Aaron Alt ·
We anticipate the 2027 percent impact to revenue growth to be generally consistent with what we observed in H2 of fiscal '26 and to have no adverse profit impact.
Aaron Alt ·
We anticipate growth in our MSO platforms, and we will benefit from the previously announced distribution wins that began to ramp in Q4 of fiscal '26.
Aaron Alt ·
How does Cardinal Health compare with its peers?
Short answer
Cardinal Health's score ranks 5th of 11 in the bounded comparison shown, against 10 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Cardinal Health is more than a pharmaceutical wholesaler. Its nuclear pharmacies, radiopharmaceutical production, specialty services, hospital pharmacy management, branded medical products, and procedure kits create service and manufacturing exposure that a pure distributor would not have.
Nor does it resemble a drug developer or a pure medical-device manufacturer: pharmaceutical distribution remains overwhelmingly dominant in the reported revenue mix, and the consolidated economics retain the high-sales, thin-margin character of distribution. The distinctive structure is a pharmaceutical logistics engine paired with smaller specialized-service and medical-product operations.
| Company | Price | Market value | Score |
|---|---|---|---|
| $919.21 Oct 2, 2026 | $57.2B | 97 5-pillar Oct 4, 2026 | |
| $42.38 Oct 2, 2026 | $2.68B | 97 5-pillar Oct 4, 2026 | |
| $85.15 Oct 2, 2026 | $49.0B | 90 5-pillar Oct 4, 2026 | |
| $902.28 Oct 2, 2026 | $106B | 90 5-pillar Oct 4, 2026 | |
| Cardinal Health (CAH) — this page | $228.30 | $53.5B | 88 |
| $309.05 Oct 2, 2026 | $60.1B | 81 5-pillar Oct 4, 2026 | |
| $8.80 Oct 2, 2026 | $38.8B | 78 5-pillar Oct 4, 2026 | |
| $84.88 Oct 2, 2026 | $9.67B | 73 5-pillar Oct 4, 2026 | |
| $176.80 Oct 2, 2026 | $48.7B | 72 5-pillar Oct 4, 2026 | |
| $45.26 Oct 2, 2026 | $2.14B | 63 5-pillar Oct 4, 2026 | |
| $0.87 Oct 2, 2026 | — | 33 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $250.00 – $292.00
- Consensus target
- $273.22
- Median target
- $275.00
Consensus record · Captured .
Measured against a quoted price of $228.30 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Aug 19, 2026
- Transactions
- 56
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 31
- Other transactions
- 25
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 88.3% Period end Jun 30, 2026
- Previous quarter · ownership
- 86.1% Prior to period end Jun 30, 2026
- Reporting holders
- 1,548 Period end Jun 30, 2026
- Previous quarter · holders
- 1,486 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 26,490,633 |
| Vanguard Capital Management LLC | 15,292,186 |
| Wellington Management Group Llp | 14,860,271 |
| Vanguard Portfolio Management LLC | 13,717,894 |
| State Street Corp | 11,967,121 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Cardinal Health (CAH)?
- Cardinal Health, McKesson Double Down on CVS Deals Through 2032
- Cardinal Health to Extend Pharmaceutical Distribution Agreement With CVS Health
- Cardinal Health Enters Into Binding LOI To Extend Existing Distribution Agreement With CVS Health Through June 30, 2032
- Cardinal Health (CAH) Stock Looks About Right At Today’s Price
Common Questions About CAH (Healthcare)
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why does Cardinal Health generate so much revenue with such a thin margin?
Pharmaceutical distribution dominates the revenue mix, so the value of medicines flowing through Cardinal Health is recorded as sales while the company retains only a narrow spread. That creates enormous reported revenue without manufacturer-like margins.
What do Cardinal Health nuclear pharmacies add to the Pharmaceutical business?
They extend the business beyond conventional drug delivery into nuclear-pharmacy management and radiopharmaceutical production. Those specialized capabilities sit alongside repackaging, specialty support, and pharmacy-management services.
Why is Cardinal Health removing the tariff refund from its earnings baseline?
Management described the refund benefit as nonrecurring and excludes it to make future periods comparable with the underlying business. Operational progress therefore needs to stand without that benefit.
How important are Cardinal Health medical products beside pharmaceutical distribution?
Pharmaceutical activity is far larger in the reported revenue mix, but the Medical operation adds branded manufacturing, sourcing, procedure kits, and supply-chain relationships across hospitals, surgical centers, and laboratories. It broadens what Cardinal Health supplies without changing the company's distribution-led economics.
What is the CAH stock price today?
The last price recorded on this page for Cardinal Health, Inc. (CAH) is $228.30, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CAH price target?
The analyst consensus price target for Cardinal Health, Inc. (CAH) is $273.22 (range $250.00 to $292.00, median $275.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are CAH's next earnings?
The next earnings date listed on this page for Cardinal Health, Inc. (CAH) is Oct 29, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (80 figures)
The 80 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Aaron Alt (Aug 11, 2026): We expect Pharma segment revenue to show 3% to 5% growth in the coming year. Aaron Alt (Aug 11, 2026): First, from a baseline perspective, for ease of comparability between fiscal '26 and our guidance for future years, we will be excluding the $0.31 of onetime positive EPS impact from the IEEPA tariff refund recognition in our just past Q4. Aaron Alt (Aug 11, 2026): We anticipate the 2027 percent impact to revenue growth to be generally consistent with what we observed in H2 of fiscal '26 and to have no adverse profit impact. Aaron Alt (Aug 11, 2026): We anticipate growth in our MSO platforms, and we will benefit from the previously announced distribution wins that began to ramp in Q4 of fiscal '26. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Dublin, OH | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "7000 Cardinal Place, Dublin, OH, 43017, US". |
FMP — 67 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $228.30 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:41.943Z. | |
px.change | Change on the day | -0.78% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $53.5B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:02.000Z. Captured from FMP at 2026-10-04T20:54:40.897Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$1.79 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2026 | $63.86B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 31.40 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.82M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.52 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Jason Hollar | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 61,344 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2022 through FY2026: FY2022 revenue $181.33B, net result −$938.00M; FY2023 revenue $204.98B, net result $330.00M; FY2024 revenue $226.83B, net result $852.00M; FY2025 revenue $222.58B, net result $1.56B; FY2026 revenue $254.25B, net result $1.71B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | GMPD $12.72B · Pharmaceutical Member $234.83B · Other Operating Segment $6.79B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 3.8% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $63.86B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $1.63B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $729.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $60.94B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $1.54B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $509.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $65.44B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $1.50B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $707.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $64.01B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $1.46B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $668.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-11.revenue_actual | Revenue · reported — report date 2026-08-11 | $63.67B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-11.revenue_estimated | Revenue · estimate — report date 2026-08-11 | $65.15B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-11.eps_actual | EPS · reported — report date 2026-08-11 | $2.9100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-11.eps_estimated | EPS · estimate — report date 2026-08-11 | $2.4200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_actual | Revenue · reported — report date 2026-04-30 | $60.94B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.revenue_estimated | Revenue · estimate — report date 2026-04-30 | $62.10B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_actual | EPS · reported — report date 2026-04-30 | $3.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-30.eps_estimated | EPS · estimate — report date 2026-04-30 | $2.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_actual | Revenue · reported — report date 2026-02-05 | $65.63B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_estimated | Revenue · estimate — report date 2026-02-05 | $65.08B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_actual | EPS · reported — report date 2026-02-05 | $2.6300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_estimated | EPS · estimate — report date 2026-02-05 | $2.3400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_actual | Revenue · reported — report date 2025-10-30 | $64.01B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.revenue_estimated | Revenue · estimate — report date 2025-10-30 | $59.24B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_actual | EPS · reported — report date 2025-10-30 | $2.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-30.eps_estimated | EPS · estimate — report date 2025-10-30 | $2.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $4.86B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $1.69B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $9.95B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $1.69B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $1.82B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$264.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$146.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $686.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$131.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $973.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$108.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $250.00 – $292.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $273.22 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $275.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 56 transactions · 0 purchases, 31 sales, 25 other transactions · 9 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Aug 19, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 88.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 86.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 1,548 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 1,486 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 26,490,633 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 15,292,186 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Wellington Management Group Llp — shares in provider snapshot | 14,860,271 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 13,717,894 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | State Street Corp — shares in provider snapshot | 11,967,121 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 29, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-08-19 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-03 | |
px.range52 | 52-week range | $151.87 – $258.30 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -55.7% · ROA 2.8% · current ratio 0.91 · earnings yield 3.1% · free-cash-flow yield 8.7% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 11.02× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $4.86B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $2.05 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.90% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-11.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($63.67B) with the recorded estimate ($65.15B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-11.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($2.9100) with the recorded estimate ($2.4200) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 88 of 100 · Exceptional · pillars 59 / 81 / 88 / 95 / 77 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 88 (stored snapshot Oct 3, 2026) → 88 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-11. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-11.revenue_actual,earn.history.depth.2026-08-11.revenue_estimated,earn.history.depth.2026-08-11.revenue_actual.comparison,earn.history.depth.2026-08-11.eps_actual.comparison,earn.history.depth.2026-08-11.eps_actual,earn.history.depth.2026-08-11.eps_estimated,earn.history.depth.2026-04-30.revenue_actual,earn.history.depth.2026-04-30.revenue_estimated,earn.history.depth.2026-04-30.eps_actual,earn.history.depth.2026-04-30.eps_estimated,earn.history.depth.2026-02-05.revenue_actual,earn.history.depth.2026-02-05.revenue_estimated,earn.history.depth.2026-02-05.eps_actual,earn.history.depth.2026-02-05.eps_estimated,earn.history.depth.2025-10-30.revenue_actual,earn.history.depth.2025-10-30.revenue_estimated,earn.history.depth.2025-10-30.eps_actual,earn.history.depth.2025-10-30.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | CARDINAL HEALTH INC Our market-data provider lists the name as "Cardinal Health, Inc."; the filer's own record is used here. | 2026-08-11 | OFFICIAL | SEC EDGAR — 10-K filed 2026-08-11 |
| Business description | Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Distribution The company's SEC filings classify it under SIC 5122 — Wholesale-Drugs, Proprietaries & Druggists' Sundries. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | GMPD: $12.72B; Pharmaceutical Member: $234.83B; Other Operating Segment: $6.79B | 2026-06-30 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Trailing twelve-month ratio set | Quick ratio: 0.49; Current ratio: 0.88; Debt to equity: -3.45; Net margin: 0.7%; Gross margin: 3.8%; Operating margin: 1%; Return on assets: 3%; Return on equity: -59.7% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Cash, investments and debt | Total debt: $9.95B; Liquidity basis: cash and short-term investments; Total liabilities: $60.02B; Cash and short-term investments: $4.86B; Cash and investments: $4.86B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-11 | FMP | Financial Modeling Prep (FMP) earnings |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-11 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $4.86B; Cash and short-term investments: $4.86B; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$5.09B; Total debt: $9.95B; Cash and investments: $4.86B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Distress and quality screens | Altman Z-score: 5.07; Piotroski F-score: 7 Altman Z below 1.8 is the conventional distress zone. For a company holding large cash against negative retained earnings the score mostly reflects the retained-earnings term. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-10-29; EPS estimate: $2.92 per share; Revenue estimate: $66.71B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold CAH
Funds in our ETF coverage that list CAH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| SMI 3Fourteen Full-Cycle Trend ETF (FCTE) | 5.30% | |
| Liberty One Tactical Income ETF (LOTI) | 2.85% | |
| JMID ETF | 2.59% | |
| SPCT ETF | 2.56% |